Evidence map›Paper›PMID 38594253›Full record

ArticleScientific reports2024

Identification of small molecules affecting the interaction between human hemoglobin and Staphylococcus aureus IsdB hemophore.

Monica Cozzi, Mariacristina Failla, Eleonora Gianquinto, Sandra Kovachka, Valeria Buoli Comani, Carlotta Compari, Omar De Bei, Roberta Giaccari, Francesco Marchesani, Marialaura Marchetti and 9 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Hemoglobin receptor redundancy inJournal of structural biology: X · 2025
    Article
  5. DisarmingPathogens (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Monica Cozzi *Department of Food and Drug, University of Parma, Parma, Italy.
Mariacristina Failla *Department of Drug Science and Technology, University of Turin, Turin, Italy.
Eleonora GianquintoDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Sandra KovachkaDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Valeria Buoli ComaniDepartment of Food and Drug, University of Parma, Parma, Italy.
Carlotta CompariDepartment of Food and Drug, University of Parma, Parma, Italy.
Omar De BeiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Roberta GiaccariDepartment of Food and Drug, University of Parma, Parma, Italy.
Francesco MarchesaniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Marialaura MarchettiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Luca RondaDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Barbara RolandoDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Massimo BaroniMolecular Discovery Ltd, Kisnetic Business Centre, Elstree, Borehamwood, Hertfordshire, UK.
Gabriele CrucianiDepartment of Chemistry, Biology and Biotechnology, University of Perugia, Perugia, Italy.
Barbara CampaniniDepartment of Food and Drug, University of Parma, Parma, Italy.
Stefano BettatiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Serena FaggianoDepartment of Food and Drug, University of Parma, Parma, Italy. serena.faggiano@unipr.it.
Loretta LazzaratoDepartment of Drug Science and Technology, University of Turin, Turin, Italy.
Francesca SpyrakisDepartment of Drug Science and Technology, University of Turin, Turin, Italy. francesca.spyrakis@unito.it.
University of Parma · ITUniversity of Turin · ITNational Research Council · ITMolecular Discovery (United Kingdom) · GBThe Herbert Wertheim UF Scripps Institute for Biomedical Innovation & TechnologyUniversity of Perugia · IT

Funding

MUR PRIN 2020AE3LTAUniversity of Turin LAZL_RILO_01_22
6 · The paper itself

Abstract

Human hemoglobin (Hb) is the preferred iron source of Staphylococcus aureus. This pathogenic bacterium exploits a sophisticated protein machinery called Iron-regulated surface determinant (Isd) system to bind Hb, extract and internalize heme, and finally degrade it to complete iron acquisition. IsdB, the surface exposed Hb receptor, is a proven virulence factor of S. aureus and the inhibition of its interaction with Hb can be pursued as a strategy to develop new classes of antimicrobials. To identify small molecules able to disrupt IsdB:Hb protein-protein interactions (PPIs), we carried out a structure-based virtual screening campaign and developed an ad hoc immunoassay to screen the retrieved set of commercially available compounds. Saturation-transfer difference (STD) NMR was applied to verify specific interactions of a sub-set of molecules, chosen based on their efficacy in reducing the amount of Hb bound to IsdB. Among molecules for which direct binding was verified, the best hit was submitted to ITC analysis to measure the binding affinity to Hb, which was found to be in the low micromolar range. The results demonstrate the viability of the proposed in silico/in vitro experimental pipeline to discover and test IsdB:Hb PPI inhibitors. The identified lead compound will be the starting point for future SAR and molecule optimization campaigns.

Indexed as

Cation Transport ProteinsStaphylococcal InfectionsHemeHemoglobinsHumansIronStaphylococcus aureusCation Transport ProteinsHemeHemoglobinsIron

Identifiers

PMID38594253
PMCPMC11003968
OpenAlexW4394611803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.